(THRM) Gentherm - Ratings and Ratios
Climate Control, Heated Seats, Lumbar Support, Thermal Management, Temperature
THRM EPS (Earnings per Share)
THRM Revenue
Description: THRM Gentherm
Gentherm Incorporated is a diversified industrial company that leverages its thermal management and pneumatic comfort technologies to serve the automotive and medical industries. The company has a strong presence in the global market, with a diverse product portfolio that includes climate comfort systems, integrated electronic components, and patient temperature management systems.
The automotive segment is a significant contributor to Gentherms revenue, with products such as seat heaters, blowers, and thermoelectric devices being used by major automakers. The companys focus on innovation has enabled it to expand its product offerings to include advanced comfort solutions like pneumatic lumbar and massage systems. Additionally, Gentherms battery performance solutions and valve systems cater to the growing demand for electric vehicles and advanced automotive technologies.
In the medical segment, Gentherms patient temperature management systems are used in hospitals and healthcare facilities to provide hyper-hypothermia therapy, normothermia in surgical procedures, and additional warming/cooling therapies. The companys products are marketed under various brand names, including Blanketrol, Kool-Kit, and Hemotherm, and are designed to meet the specific needs of medical professionals.
From a technical analysis perspective, Gentherms stock price has been trending upwards, with the SMA20 and SMA50 indicators suggesting a bullish sentiment. However, the SMA200 indicator is significantly higher, indicating a potential resistance level. The ATR indicator suggests a moderate level of volatility, with a 3.07% daily price movement. Based on the technical data, a potential trading strategy could be to buy on dips, targeting the 52W High of $55.18.
Fundamentally, Gentherms market capitalization is approximately $857.29M, with a P/E ratio of 17.47 and a forward P/E ratio of 13.30. The companys RoE is 7.80%, indicating a relatively stable return on equity. Using a combination of technical and fundamental analysis, a forecast for Gentherms stock price could be made. Assuming a continued upward trend in the automotive and medical industries, Gentherms revenue is likely to grow, driving the stock price higher. Based on the P/E ratio and forward P/E ratio, a target price range of $30-$35 could be estimated, representing a potential upside of 8-15% from the current price.
Taking into account both the technical and fundamental data, a potential trading strategy could be to accumulate Gentherms stock on dips, targeting a medium-term price target of $32-$35. This strategy is based on the assumption that the companys strong product portfolio, diversified revenue streams, and growing demand in the automotive and medical industries will drive the stock price higher.
THRM Stock Overview
| Market Cap in USD | 999m |
| Sub-Industry | Automotive Parts & Equipment |
| IPO / Inception | 1993-06-10 |
THRM Stock Ratings
| Growth Rating | -48.8% |
| Fundamental | 56.6% |
| Dividend Rating | - |
| Total Return vs S&P 500 | -41.2% |
| Analyst Rating | 3.83 of 5 |
THRM Dividends
Currently no dividends paidTHRM Growth Ratios
| Growth Correlation 3m | 93.8% |
| Growth Correlation 12m | -83.3% |
| Growth Correlation 5y | -71.6% |
| CAGR 5y | -4.20% |
| CAGR/Max DD 5y | -0.05 |
| Sharpe Ratio 12m | -0.35 |
| Alpha | -41.88 |
| Beta | 0.531 |
| Volatility | 43.39% |
| Current Volume | 112.9k |
| Average Volume 20d | 282.5k |
| Stop Loss | 33.4 (-4.7%) |
| Signal | -0.39 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (31.6m TTM) > 0 and > 6% of Revenue (6% = 87.2m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 0.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 26.28% (prev 24.82%; Δ 1.46pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 114.5m > Net Income 31.6m (YES >=105%, WARN >=100%) |
| Net Debt (-67.1m) to EBITDA (132.1m) ratio: -0.51 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (30.7m) change vs 12m ago -3.33% (target <= -2.0% for YES) |
| Gross Margin 24.58% (prev 25.44%; Δ -0.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 111.7% (prev 118.1%; Δ -6.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.56 (EBITDA TTM 132.1m / Interest Expense TTM 7.57m) >= 6 (WARN >= 3) |
Altman Z'' 5.03
| (A) 0.28 = (Total Current Assets 758.8m - Total Current Liabilities 376.9m) / Total Assets 1.36b |
| (B) 0.51 = Retained Earnings (Balance) 696.1m / Total Assets 1.36b |
| (C) 0.06 = EBIT TTM 79.9m / Avg Total Assets 1.30b |
| (D) 1.06 = Book Value of Equity 698.2m / Total Liabilities 661.7m |
| Total Rating: 5.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 56.64
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 4.36% = 2.18 |
| 3. FCF Margin 3.27% = 0.82 |
| 4. Debt/Equity 0.31 = 2.45 |
| 5. Debt/Ebitda 1.66 = 0.66 |
| 6. ROIC - WACC -0.59% = -0.74 |
| 7. RoE 4.82% = 0.40 |
| 8. Rev. Trend 47.30% = 2.37 |
| 9. Rev. CAGR 4.05% = 0.51 |
| 10. EPS Trend data missing |
| 11. EPS CAGR -62.44% = -2.50 |
What is the price of THRM shares?
Over the past week, the price has changed by +7.22%, over one month by +14.88%, over three months by +26.63% and over the past year by -31.58%.
Is Gentherm a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of THRM is around 32.58 USD . This means that THRM is currently overvalued and has a potential downside of -7.05%.
Is THRM a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the THRM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 42.6 | 21.5% |
| Analysts Target Price | 38 | 8.4% |
| ValueRay Target Price | 35.6 | 1.6% |
Last update: 2025-08-12 02:56
THRM Fundamental Data Overview
CCE Cash And Equivalents = 128.3m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 32.4158
P/E Forward = 15.1515
P/S = 0.6875
P/B = 1.428
P/EG = 0.71
Beta = 1.449
Revenue TTM = 1.45b USD
EBIT TTM = 79.9m USD
EBITDA TTM = 132.1m USD
Long Term Debt = 209.0m USD (from longTermDebt, last quarter)
Short Term Debt = 10.1m USD (from shortTermDebt, last quarter)
Debt = 219.1m USD (Calculated: Short Term 10.1m + Long Term 209.0m)
Net Debt = -67.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.09b USD (999.2m + Debt 219.1m - CCE 128.3m)
Interest Coverage Ratio = 10.56 (Ebit TTM 79.9m / Interest Expense TTM 7.57m)
FCF Yield = 4.36% (FCF TTM 47.5m / Enterprise Value 1.09b)
FCF Margin = 3.27% (FCF TTM 47.5m / Revenue TTM 1.45b)
Net Margin = 2.18% (Net Income TTM 31.6m / Revenue TTM 1.45b)
Gross Margin = 24.58% ((Revenue TTM 1.45b - Cost of Revenue TTM 1.10b) / Revenue TTM)
Tobins Q-Ratio = 1.56 (Enterprise Value 1.09b / Book Value Of Equity 698.2m)
Interest Expense / Debt = -1.85% (Interest Expense -4.04m / Debt 219.1m)
Taxrate = 36.49% (from yearly Income Tax Expense: 37.3m / 102.3m)
NOPAT = 50.7m (EBIT 79.9m * (1 - 36.49%))
Current Ratio = 2.01 (Total Current Assets 758.8m / Total Current Liabilities 376.9m)
Debt / Equity = 0.31 (Debt 219.1m / last Quarter total Stockholder Equity 699.7m)
Debt / EBITDA = 1.66 (Net Debt -67.1m / EBITDA 132.1m)
Debt / FCF = 4.61 (Debt 219.1m / FCF TTM 47.5m)
Total Stockholder Equity = 656.0m (last 4 quarters mean)
RoA = 2.32% (Net Income 31.6m, Total Assets 1.36b )
RoE = 4.82% (Net Income TTM 31.6m / Total Stockholder Equity 656.0m)
RoCE = 9.23% (Ebit 79.9m / (Equity 656.0m + L.T.Debt 209.0m))
RoIC = 5.73% (NOPAT 50.7m / Invested Capital 884.4m)
WACC = 6.33% (E(999.2m)/V(1.22b) * Re(7.97%)) + (D(219.1m)/V(1.22b) * Rd(-1.85%) * (1-Tc(0.36)))
Shares Correlation 5-Years: -100.0 | Cagr: -1.80%
Discount Rate = 7.97% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 74.97% ; FCFE base≈41.5m ; Y1≈33.9m ; Y5≈24.0m
Fair Price DCF = 14.55 (DCF Value 444.0m / Shares Outstanding 30.5m; 5y FCF grow -21.97% → 3.0% )
Revenue Correlation: 47.30 | Revenue CAGR: 4.05%
Revenue Growth Correlation: -71.30%
EPS Correlation: N/A | EPS CAGR: -62.44%
EPS Growth Correlation: 12.61%
Additional Sources for THRM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle